# Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint

> **NCT00613730** · PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 3 (actual)

## Conditions studied

- Cancer of Pancreas
- Cancer of the Pancreas
- Pancreas Cancer
- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** panitumumab

## Key facts

- **NCT ID:** NCT00613730
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** APPRISE closure prompted by SWOG S0205 not meeting primary endpoint-improving OS. APPRISE enrollment closure due to similar design;no unexpected safety data
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00613730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00613730, "Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00613730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*